SymBio Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
SymBio Pharmaceuticals has a total shareholder equity of ¥5.2B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥6.1B and ¥910.0M respectively.
Key information
0%
Debt to equity ratio
JP¥0
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥5.13b |
| Equity | JP¥5.16b |
| Total liabilities | JP¥910.00m |
| Total assets | JP¥6.07b |
Recent financial health updates
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely
Sep 24
Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation
Feb 09Recent updates
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely
Sep 24SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up
Aug 06Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge
Jun 11Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation
Feb 09If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%
Dec 18Financial Position Analysis
Short Term Liabilities: 4582's short term assets (¥6.0B) exceed its short term liabilities (¥906.0M).
Long Term Liabilities: 4582's short term assets (¥6.0B) exceed its long term liabilities (¥4.0M).
Debt to Equity History and Analysis
Debt Level: 4582 is debt free.
Reducing Debt: 4582 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4582 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 4582 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 34.4% each year